ALTMETME Pharma N.V.ALTME info
$0.17info-0.65%24h
Global rank35470
Market cap$2.96M
Change 7d6.21%
YTD Performance-35.29%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    TME Pharma N.V. (ALTME) Stock Overview

    TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck Sharp & Dohme Corp. to study NOX-A12 combined with Keytruda and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is based in Berlin, Germany.

    ALTME Stock Information

    Symbol
    ALTME
    Address
    Max-Dohrn-Strasse 8-10Berlin, 10589Germany
    Founded
    -
    Trading hours
    -
    Website
    https://www.tmepharma.com
    Country
    πŸ‡©πŸ‡ͺ Germany
    Phone Number
    49 30 726247 0

    TME Pharma N.V. (ALTME) Price Chart

    -
    Value:-

    TME Pharma N.V. Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.17116816716683336
    N/A
    Market Cap
    $2.96M
    N/A
    Shares Outstanding
    17.31M
    N/A
    Employees
    13.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org